{
    "organizations": [],
    "uuid": "2ab7d77b44cda86aa3b1248bd789831d714757bc",
    "author": "",
    "url": "https://www.reuters.com/article/brief-bellicum-announces-update-on-clini/brief-bellicum-announces-update-on-clinical-hold-of-u-s-bpx-501-studies-idUSASB0C78W",
    "ord_in_thread": 0,
    "title": "BRIEF-Bellicum Announces Update On Clinical Hold Of U.S. BPX-501 Studies",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 04 PM / Updated 8 minutes ago BRIEF-Bellicum Announces Update On Clinical Hold Of U.S. BPX-501 Studies Reuters Staff Feb 23 (Reuters) - Bellicum Pharmaceuticals Inc: * BELLICUM ANNOUNCES UPDATE ON CLINICAL HOLD OF U.S. BPX-501 STUDIES * BELLICUM - RECEIVED NOTIFICATION FROM FDA OUTLINING CRITERIA REQUIRED FOR LIFTING CLINICAL HOLD ON U.S. STUDIES OF BPX-501 * BELLICUM PHARMACEUTICALS INC - CLINICAL HOLD DOES NOT AFFECT COMPANYâ€˜S BP-004 REGISTRATION TRIAL IN EUROPE * BELLICUM - PLANS TO IMPLEMENT REVISIONS TO U.S. STUDY PROTOCOLS, ADDITION OF MORE COMPREHENSIVE MONITORING, MANAGEMENT OF NEUROTOXICITY FOR BPX-501 Source text for Eikon: Further company coverage:",
    "published": "2018-02-23T14:03:00.000+02:00",
    "crawled": "2018-02-23T14:20:58.024+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "announces",
        "update",
        "clinical",
        "hold",
        "study",
        "reuters",
        "staff",
        "feb",
        "reuters",
        "bellicum",
        "pharmaceutical",
        "inc",
        "bellicum",
        "announces",
        "update",
        "clinical",
        "hold",
        "study",
        "bellicum",
        "received",
        "notification",
        "fda",
        "outlining",
        "criterion",
        "required",
        "lifting",
        "clinical",
        "hold",
        "study",
        "bellicum",
        "pharmaceutical",
        "inc",
        "clinical",
        "hold",
        "affect",
        "company",
        "registration",
        "trial",
        "europe",
        "bellicum",
        "plan",
        "implement",
        "revision",
        "study",
        "protocol",
        "addition",
        "comprehensive",
        "monitoring",
        "management",
        "neurotoxicity",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}